Literature DB >> 25729896

Correction: poloxomer 188 has a deleterious effect on dystrophic skeletal muscle function.

.   

Abstract

Entities:  

Year:  2015        PMID: 25729896      PMCID: PMC4346404          DOI: 10.1371/journal.pone.0119252

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
The following information is missing from the Competing Interest section: The authors have the following competing interests to declare: Dr. Wells is on the Scientific Advisory Board of Akashi Therapeutics (was Dart Therapeutics), a company developing treatments for Duchenne muscular dystrophy. Dr. Wells is also a member of the Treat-NMD Advisory Committee for Therapeutics that provides confidential guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials. In the title and abstract of this article, the word “Poloxomer” should be “Poloxamer.” The correct title is “Poloxamer 188 Has a Deleterious Effect on Dystrophic Skeletal Muscle Function.” The correct citation is: Terry RL, Kaneb HM, Wells DJ (2014) Poloxamer 188 Has a Deleterious Effect on Dystrophic Skeletal Muscle Function. PLoS ONE 9(3): e91221. doi:10.1371/journal.pone.0091221
  1 in total

1.  Poloxamer [corrected] 188 has a deleterious effect on dystrophic skeletal muscle function.

Authors:  Rebecca L Terry; Hannah M Kaneb; Dominic J Wells
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.